Inhibition of Hec1 as a novel approach for treatment of primary liver cancer

Lynn Yl Huang,Chia-Chi Chang,Ying-Shuan Lee,Jiann-Jyh Huang,Shih-Hsien Chuang,Jia-Ming Chang,Kuo-Jang Kao,Gillian M. Lau,Pei-Yi Tsai,Chia-Wei Liu,Her-Sheng Lin,Robert G. Gish,Johnson Yn Lau

Inhibition of Hec1 as a novel approach for treatment of primary liver cancer

2014

Lynn Yl Huang
Chia-Chi Chang
Ying-Shuan Lee
Jiann-Jyh Huang
Shih-Hsien Chuang
Jia-Ming Chang
Kuo-Jang Kao
Gillian M. Lau
Pei-Yi Tsai
Chia-Wei Liu
Her-Sheng Lin
Robert G. Gish
Johnson Yn Lau

Purpose Highly expressed in cancer protein 1 (Hec1) is an oncogene and a promising molecular target for novel anticancer drugs. The purpose of this study was to evaluate the potential of a Hec1 inhibitor, TAI-95, as a treatment for primary liver cancer.

Keywords:

Liver cancer
Cancer
Pharmacology
Oncogene
Biology
anticancer drug
pharmacology toxicology
primary liver cancer
molecular targets
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations